Article

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.

Department of Haematology, Karolinska University Hospital, Stockholm, Sweden.
British Journal of Haematology (Impact Factor: 4.96). 12/2006; 135(3):367-73. DOI: 10.1111/j.1365-2141.2006.06302.x
Source: PubMed

ABSTRACT Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted; 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations.

0 Bookmarks
 · 
108 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Induced pluripotent stem cells (iPSCs) derived from disease cells are expected to provide a new experimental material, especially for the diseases of which the sample is difficult to obtain. In this study, we generated iPSCs from primary and secondary myelofibrosis patient samples. The primary myelofibrosis (PMF) disease cells had chromosome 13q deletion and the secondary myelofibrosis (SMF) disease cells had JAK2V617F mutation. The myelofibrosis patient cell-derived iPSCs (MF-iPSCs) were confirmed to possess these parental disease specific genomic markers. The capacity to form three germ layers was confirmed by teratoma assay. By co-culture with specific feeder cells and cytokines, MF-iPSCs can re-differentiate into blood progenitor cells and finally into megakaryocytes. We found that messengerribonucleic acid (mRNA) levels of IL-8, one of candidate cytokines related to the pathogenesis of myelofibrosis, was expressedelevated predominantly in megakaryocytes derived from MF-iPSCs. Because megakaryocytes from myelofibrosis clones are considered to produce critical mediators to proliferate fibroblasts in the bone marrow and iPSCs can provide differentiated cells abundantly, disease specific iPSCs we established should be a good research tool for this intractable disease.
    Experimental Hematology 09/2014; · 2.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Haematologica 2012 [Epub ahead of print] Citation: Ditschkowski M, Elmaagacli AH, Trenschel R, Gromke T, Steckel NK, Koldehoff M, and Beelen DW. DIPSS scores, pre-transplant therapy and chronic GVHD determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica. 2012; 97:xxx doi:10.3324/haematol.2011.061168 Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process. Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haemato-logica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organiza-tion, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature.
  • [Show abstract] [Hide abstract]
    ABSTRACT: From 2007 to 2011, 66 patients with primary myelofibrosis (PMF) or MF preceded by essential thrombocythemia or polycythemia vera were enrolled into a prospective phase II clinical trial of reduced intensity allogeneic hematopoietic stem cell transplantation (AHSCT), Myeloproliferative Disorder Research Consortium -101 trial. The study included patients with sibling donors (n=32) receiving fludarabine/melphalan (FluMel) as a preparative regimen and patients with unrelated donors (n=34) receiving conditioning with FluMel+anti-thymocyte globulin (rATG). Patient characteristics in the two cohorts were similar. Engraftment occurred in 97% of siblings and 76% unrelated transplants, while secondary graft failure occurred in 3% and 12%, respectively. With a median follow-up of 25 months for patients alive, the overall survival was 75% in the sibling (median not reached) and 32% in the unrelated group (median OS: 6 months, 95% CI:3,25) (HR 3.9, 95% CI: 1.8,8.9) (p<0.001). Non-relapse-mortality was 22% in siblings and 59% in unrelated AHSCT. Survival correlated with type of donor, but not with the degree of histocompatibility match, age or JAK2(V617F)-status. In patients with myelofibrosis with sibling donors AHSCT is an effective therapeutic option while AHSCT from unrelated donors with FluMel+ATG conditioning led to high rate of graft failure and limited survival. This study was registered at clinicaltrials.gov, identifier: 00572897.
    Blood 06/2014; · 9.78 Impact Factor

Full-text (2 Sources)

Download
9 Downloads
Available from
Sep 9, 2014